Investigating the link between PCSK9 gene variations and cardiac rupture risk after heart attacks
PCSK9 Polymorphism and Risk of Mechanical Complications Following Acute Myocardial Infarction
Maastricht University Medical Center · NCT05503095
This study is trying to see if differences in the PCSK9 gene can help explain why some people have a higher risk of heart rupture after a heart attack.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Maastricht University Medical Center (other) |
| Locations | 1 site (Varese) |
| Trial ID | NCT05503095 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the relationship between PCSK9 gene polymorphisms and the risk of cardiac rupture following acute myocardial infarction (AMI). It focuses on patients diagnosed with AMI, both with and without complications of cardiac rupture, to identify genetic factors that may contribute to these severe outcomes. The study involves genetic analysis to assess variations in the PCSK9 gene, which has been implicated in cholesterol regulation and may play a role in heart tissue response to ischemia. By understanding these genetic influences, the study seeks to clarify why some patients experience life-threatening complications while others do not.
Who should consider this trial
Good fit: Ideal candidates include individuals with a clinical diagnosis of acute myocardial infarction, particularly those experiencing complications such as cardiac rupture.
Not a fit: Patients without coronary artery disease or those not diagnosed with acute myocardial infarction will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved risk stratification and targeted interventions for patients at high risk of cardiac rupture after heart attacks.
How similar studies have performed: While the role of PCSK9 in cholesterol metabolism is well-established, the specific investigation of its polymorphisms in relation to cardiac rupture is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * clinical diagnosis of acute myocardial infarction with ST sopra-elevation (control group) * clinical diagnosis of acute myocardial infarction complicated by cardiac rupture Exclusion Criteria: * absence of coronary artery disease
Where this trial is running
Varese
- Matteo Matteucci — Varese, Italy (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Post-Infarction Heart Rupture, Gene Polymorphism, PCSK9, Cardiac rupture